Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 14/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28520193 | 0.81 | HTR1D (0.42) | NTSR1HTR2C | |
| SCHEMBL5220798 | 0.81 | HTR1D (0.42) | NTSR1HTR2C | |
| Hydrochloric Acid SCHEMBL28502715 | 0.79 | HTR1D (0.41) | NTSR1HTR2C | |
| Hydrochloric Acid SCHEMBL28515535 | 0.79 | HTR1D (0.41) | NTSR1HTR2C | |
| SCHEMBL15818392 | 0.78 | HTR2C (0.59) | HTR2C | |
| SCHEMBL6605558 | 0.77 | MEN1 (0.47) | NTSR1ALDH1A1TP53GAAMAPT | |
| Hydrochloric Acid SCHEMBL7666084 | 0.76 | HTR2C (0.61) | HTR2C | |
| SCHEMBL17376277 | 0.76 | GRIN2D (0.40) | NTSR1SMPD3 | |
| SCHEMBL12554645 | 0.76 | HTR1D (0.38) | ESR2ALDH1A1TP53GAAMAPT | |
| SCHEMBL1509720 | 0.72 | ESR2 (0.47) | ESR2ALDH1A1GAAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130392-A1 | Method of Administering a Methylene Blue - Curcumin Analog for the Treatment of Alzheimer's Disease | DEPUY SPINE, LLC | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130392-A1 | Method of Administering a Methylene Blue - Curcumin Analog for the Treatment of Alzheimer's Disease | APP, PSEN2, MAPT | NTSR1 2857/4885ESR2 1351/4885ALDH1A1 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.